scispace - formally typeset
L

Luca Valenti

Researcher at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Publications -  453
Citations -  23444

Luca Valenti is an academic researcher from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. The author has contributed to research in topics: Fatty liver & Nonalcoholic fatty liver disease. The author has an hindex of 68, co-authored 373 publications receiving 16695 citations. Previous affiliations of Luca Valenti include Columbia University & Mario Negri Institute for Pharmacological Research.

Papers
More filters
Journal ArticleDOI

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.

TL;DR: A panel of international experts from 22 countries propose a new definition of metabolic-dysfunction-associated fatty liver disease that is both comprehensive yet simple for the diagnosis of MAFLD and is independent of other liver diseases.
Journal ArticleDOI

Genomewide Association Study of Severe Covid-19 with Respiratory Failure.

David Ellinghaus, +145 more
TL;DR: A 3p21.31 gene cluster is identified as a genetic susceptibility locus in patients with Covid-19 with respiratory failure and a potential involvement of the ABO blood-group system is confirmed.
Journal ArticleDOI

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.

TL;DR: Normal ALT is not a valuable criterion to exclude patients from liver biopsy, and Alterations in glucose metabolism and insulin resistance in subjects with normal ALT should also be considered in the selection of NAFLD cases for histological assessment of disease severity and progression.
Journal ArticleDOI

Genetics and epigenetics of NAFLD and NASH: Clinical impact

TL;DR: The status of research into important genetic and epigenetic modifiers of NAFLD progression are discussed and the potential to translate the accumulating wealth of genetic data into the design of novel therapeutics and the clinical implementation of diagnostic/prognostic biomarkers will be explored.